Patent ID: 11965039
Assignee: ZP SPV 3 K/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 21:
22. A compstatin analogue according to claim 1 comprising a sequence selected from the group consisting of:, (SEQ ID NO: 214)

[K*]GSAIC(1)IWQDWGEHRC(1)TEGE,

(Compound 100)

 

(SEQ ID NO: 215)

ASGEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*],

(Compound 113)

 

(SEQ ID NO: 216)

EFC(1)I[1-Me-Trp]QDWGEHRC(1)EGE-[K*],

(Compound 134)

 

(SEQ ID NO: 217)

EGSAIC(1)IWQDWGEHRC(1)TEG-[K*],

(Compound 101)

 

(SEQ ID NO: 218)

EGSAYC(1)I[1-Me-Trp]QDWGEH[K*]C(1)[Sar]E,

(Compound 103)

 

(SEQ ID NO: 219)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EG-[K*],

(Compound 104)

 

(SEQ ID NO: 220)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*],

(Compound 109)

 

(SEQ ID NO: 221)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGK-[K*],

(Compound 110)

 

(SEQ ID NO: 222)

EGSAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[vGlu]-[K*],

(Compound 111)

 

(SEQ ID NO: 223)

FC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES[K*],

(Compound 102)

 

(SEQ ID NO: 224)

IC(1)IWQDWGEHRC(1)TEG-[K*],

(Compound 92)

 

(SEQ ID NO: 225)

IC(1)IWQDWGEHRC(1)TEGE-[K*],

(Compound 94)

 

(SEQ ID NO: 226)

SAYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E-[K*],

(Compound 105)

 

(SEQ ID NO: 227)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*],

(Compound 119)

 

(SEQ ID NO: 228)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*],

(Compound 123)

 

(SEQ ID NO: 229)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGEGGG-[K*],

(Compound 129)

 

(SEQ ID NO: 230)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]-[K*],

(Compound 138)

 

(SEQ ID NO: 231)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3]ES-[K*],

(Compound 140)

 

(SEQ ID NO: 232)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*],

(Compound 127)

 

(SEQ ID NO: 233)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGESES-[K*],

(Compound 139)

 

(SEQ ID NO: 234)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EK[vGlu]GGG-[K*],

(Compound 132)

 

(SEQ ID NO: 235)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE-[8-aminooctanoyl]-[K*],

(Compound 136)

 

(SEQ ID NO: 236)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE-[8-aminooctanoyl]-E-[K*],

(Compound 137)

 

(SEQ ID NO: 237)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGEGGG-[K*],

(Compound 130)

 

(SEQ ID NO: 238)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3]ES-[K*],

(Compound 142)

 

(SEQ ID NO: 239)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEGE[Peg3][Peg3 ]-[K*],

(Compound 126)

 

(SEQ ID NO: 240)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TEK[γGlu]GGG-[K*],

(Compound 133)

 

(SEQ ID NO: 241)

SEFC(1)I[1-Me-Trp]QDWGEHRC(1)TGAES-[K*],

(Compound 135)

 

(SEQ ID NO: 242)

SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA-[K*],

(Compound 120)

 

(SEQ ID NO: 243)

SEFC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3][K*],

(Compound 124)

 

(SEQ ID NO: 244)

SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-[K*],

(Compound 112)

 

(SEQ ID NO: 245)

SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*],

(Compound 117)

 

(SEQ ID NO: 246)

SEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGE-[K*],

(Compound 114)

 

(SEQ ID NO: 247)

SEYC(1)I[1-Me-Trp]QEW[Sar]EHRC(1)[Sar]EK[γGlu]A[K*],

(Compound 121)

 

(SEQ ID NO: 248)

SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGA[K*],

(Compound 122)

 

(SEQ ID NO: 249)

SEYC(1)I[1-Me-Trp]QEWGEHRC(1)[Sar]EGE[Peg3][Peg3]-[K*],

(Compound 125)

 

(SEQ ID NO: 250)

EGSEYC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]E,

(Compound 107)

 

(SEQ ID NO: 251)

ESSAIC(1)IWQDWGEHRC(1)TEGE,

(Compound 99)

 

(SEQ ID NO: 252)

SEFC(1)1[1-Me-Trp]QDWGEHRC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K*],

(Compound 143)

 

(SEQ ID NO: 253)

SEFC(1)I[1-Me-Trp]QDW[Sar]EHRC(1)[Sar]E[Peg3][Peg3]-[K*], and

(Compound 144)

 

(SEQ ID NO: 254)

EFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EA[Peg3][Peg3]-[K*].

(Compound 145)